This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
BCL11B / B-cell lymphoma/leukemia 11B · IHC design guide
Design Immunohistochemistry for BCL11B
Plan paraffin-section BCL11B IHC around nuclear staining in subsets of lymphoid, squamous epithelial and neuronal cells (HPA tissue IHC). Start within the catalog antibody’s 2–5 μg/ml IHC range (datasheet A01485-2) and score nuclear staining with appropriate controls.
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
BCL11B Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear staining in subsets of tissue cells (HPA tissue IHC) | |
| Staining pattern | Nuclei in subsets of lymphoid, squamous, neuronal and testis cells (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A01485-2) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A01485-2) | |
| Caveat | Subset staining; RNA concordance is medium (HPA tissue IHC) | |
| Regulation | High in brain and malignant T-cell lines (UniProt) | |
| Isoform / epitope | Two isoforms; verify epitope coverage (UniProt) |
Section 1
Recommended BCL11B IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by published BCL11B staining methods for HCC tissue (PMC10417273), Ewing sarcoma samples (PMC7139395), and mouse embryonic head sections (PMC3358280).
| Sample | Paraffin-embedded human bladder urothelial carcinoma with squamous differentiation tissue; fixative not specified (datasheet A01485-2) |
| Fixation | Image fixative and duration unreported (datasheet A01485-2); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A01485-2); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A01485-2) |
| Primary antibody | Rabbit anti-BCL11B, 2-5 μg/ml (datasheet A01485-2) |
| Primary incubation | Overnight at 4 °C (datasheet A01485-2) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A01485-2) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | BCL11B-positive staining in non-germinal center cells of appendix (HPA tissue IHC: High). HPA tissue profile: Nuclear expression in a subset of lymphoid cells, squamous epithelia, neurons and testis. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat retrieval for the catalog antibody (datasheet A01485-2). The Ewing sarcoma method specifies microwave retrieval in Target Retrieval Solution S1699 (PMC7139395).
Section 2
What Is the Expected BCL11B Staining Pattern?
BCL11B is a nuclear protein with no transmembrane segment (UniProt Q9C0K0: subcellular location and topology). In paraffin-section IHC, expect staining in subsets of lymphoid cells, squamous epithelial cells and neurons (HPA: tissue IHC profile). HPA rates its tissue profile Enhanced, while reporting medium consistency with RNA data and pending external verification (HPA: tissue IHC reliability). Interpret staining by cell type and compartment together.
| Distinct nuclear staining in a subset of non-germinal center cells in appendix or lymph node (HPA: High in these cells). | This fits the strongest listed lymphoid IHC pattern. A mixture of stained and unstained cells is expected because HPA describes expression in a subset of lymphoid cells (HPA: tissue IHC profile). Assess the intended cells rather than requiring every lymphoid cell to stain. |
| Nuclear staining in neuronal cells of caudate, cerebral cortex or hippocampus, or squamous epithelial cells of cervix, esophagus or oral mucosa (HPA: Medium in each). | These are supported positive patterns at a lower reported level than the listed High lymphoid examples (HPA: tissue IHC). Compare signal within the named cell population; the HPA level does not guarantee identical chromogen intensity in every section. |
| Predominantly cytoplasmic signal, with little convincing nuclear signal (UniProt Q9C0K0: Nucleus; HPA: nuclear tissue profile). | This conflicts with the expected compartment and warrants an artefact check. Review morphology, counterstain and negative controls before scoring it as BCL11B; cytoplasmic colour alone is insufficient evidence of specific staining (general IHC practice). |
| Strong colour in a cell population HPA lists as not detected, such as adipocytes in adipose tissue (HPA: Not detected in adipocytes). | Consider cross-reactivity or endogenous detection activity, especially if the colour also appears in a no-primary control (general IHC practice). HPA reports the assessed cell population, so do not infer that every cell in that tissue must be negative. |
| Diffuse colour across cells and extracellular space, or no signal in the expected non-germinal center cells of appendix or lymph node (HPA: High in these cells). | Diffuse colour is difficult to assign to nuclei and suggests background; absent positive-control signal leaves a negative result uninterpretable (general IHC practice). Check controls and staining conditions before drawing a biological conclusion. |
💡Expected BCL11B appearanceCall positive when chromogen is concentrated in nuclei of the expected cell population—particularly High non-germinal center cells in appendix or lymph node (HPA: tissue IHC; UniProt Q9C0K0: Nucleus); diffuse or predominantly cytoplasmic colour is a suspect positive (general IHC practice).
| Cell distribution and level | HPA reports High staining in non-germinal center cells of appendix and lymph node, Medium in listed neurons and squamous epithelia, and a subset-based nuclear profile (HPA: tissue IHC). Choose a control by its named cell population; an adjacent cell need not match its intensity. |
| Compartment and topology | UniProt places BCL11B in the nucleus and lists no transmembrane segment (UniProt Q9C0K0: subcellular location and topology). HPA tissue IHC also reports nuclear expression (HPA: tissue IHC profile). Score nuclear signal, not membrane or cytoplasmic colour. |
| Isoforms and modifications | UniProt lists 2 isoforms and modified residues, including phosphorylation sites (UniProt Q9C0K0: isoforms and modified residues). The supplied record does not map the antibody epitope or show whether either feature changes IHC detection; do not use them to explain a weak section. |
| IHC evidence and limits | HPA lists antibody HPA049117 as IHC Enhanced; that validation category reflects reproduction by independent antibodies or orthogonal data (HPA: antibody validation). The tissue profile still has medium RNA–staining consistency and awaits external verification (HPA: tissue IHC reliability). |
| Antigen retrieval | No BCL11B-specific retrieval condition or fixation sensitivity is supplied. Select retrieval conditions using a positive tissue and appropriate controls, then record the condition used (general IHC practice). A change in signal after retrieval alone does not establish a BCL11B-specific fixation effect. |
| IF/ICC Q&A | Where should IF/ICC signal localize? Mainly to the nucleoplasm, with an additional approved nucleoli fibrillar-center location (HPA: subcellular ICC-IF). That observation supports a compartment check; this IHC section supplies no IF/ICC protocol. |
| Situation | Likely cause | Next action |
|---|---|---|
| No nuclear signal in non-germinal center cells of appendix or lymph node (HPA: High in these cells). | The run may have insufficient detection or a failed staining step; tissue identity and cell selection also need checking (general IHC practice). | Confirm the named cells on the counterstain, check the positive control and run controls, then review the recorded retrieval, antibody dilution and detection steps (general IHC practice). Do not score the sample negative until the control works. |
| Signal is mainly cytoplasmic despite preserved nuclear morphology (UniProt Q9C0K0: Nucleus). | The compartment conflicts with UniProt and HPA's nuclear tissue profile; nonspecific staining or chromogen deposition is possible (HPA: tissue IHC profile; general IHC practice). | Check a no-primary control, inspect staining at nuclear boundaries, and reassess blocking and washing (general IHC practice). Require convincing nuclear signal in an expected positive cell population before scoring. |
| Colour appears broadly in HPA-listed negative cells, such as adipocytes in adipose tissue (HPA: Not detected in adipocytes). | Cross-reactivity or endogenous detection activity is possible; the listed HPA result applies to adipocytes, not every cell in adipose tissue (HPA: tissue IHC; general IHC practice). | Compare the same cell type with no-primary and other detection controls; review endogenous-activity blocking for the chosen detection system (general IHC practice). Interpret unexpected staining cautiously if controls remain clean. |
| Diffuse background obscures nuclei in a chromogenic section. | Background can follow excessive reagent concentration, inadequate blocking or incomplete washing (general IHC practice). It cannot be assigned to BCL11B from distribution alone. | Inspect the negative controls and adjust antibody concentration, blocking or wash conditions within the validated IHC workflow (general IHC practice). Reassess whether nuclei in an expected positive population remain distinct. |
| Only some lymphoid cells stain while neighboring cells remain unstained (HPA: subset of lymphoid cells). | A subset pattern can be the expected result; HPA specifically reports High staining in non-germinal center cells of appendix and lymph node (HPA: tissue IHC). | Use morphology and the counterstain to identify the scored population, then record the fraction and intensity of nuclear-positive cells (general IHC practice). Do not treat mixed staining alone as assay failure. |
| An IF/ICC image shows nucleolar signal as well as nucleoplasmic signal (HPA: subcellular ICC-IF). | HPA approves the nucleoplasm as the main location and the nucleoli fibrillar center as an additional location (HPA: subcellular ICC-IF). | Check that nuclear structures are resolved and compare with imaging controls (general IF practice). Use the dedicated IF/ICC guide for that application; assess chromogenic paraffin-section results against the HPA tissue IHC pattern. |
Experiment evidence
IHC & IF images showing BCL11B staining
A01485-2 · IHCIHC analysis of BCL11B using anti-BCL11B antibody (A01485-2). BCL11B was detected in a paraffin-embedded section of human bladder urothelial
A01485-2 · IHCIHC analysis of BCL11B using anti-BCL11B antibody (A01485-2). BCL11B was detected in a paraffin-embedded section of human breast cancer tiss
A01485-2 · IFIF analysis of BCL11B using anti-BCL11B antibody (A01485-2) and anti-Tubulin Alpha antibody (M03989-3). BCL11B was detected in immunocytoche
M01485-2 · IHCMouse spleen was stained with anti-Ctip2 rabbit antibody
M01485-2 · IHCRat spleen was stained with anti-Ctip2 rabbit antibody
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000127152-BCL11B/tissue/cerebral+cortex#imid_13484231
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000127152-BCL11B/tissue/colon#imid_13484157
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000127152-BCL11B/tissue/liver#imid_13484142
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000127152-BCL11B/tissue/kidney#imid_13484159
HPA · ICC-IF MCF-7Human Protein Atlas immunofluorescence, MCF-7, antibody HPA049117; green = BCL11B, blue = nucleus, red = microtubules.
HPA · ICC-IF MCF-7Human Protein Atlas immunofluorescence, MCF-7, antibody HPA049117; green = BCL11B, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for BCL11B IHC & IF
🧪Run lymph node first and require nuclear staining in non-germinal center cells (HPA: High in lymph node non-germinal center cells; UniProt Q9C0K0: nucleus). Use adipose tissue adipocytes as the negative tissue (HPA: Not detected in adipocytes); on the positive slide, internal negative cells should lack convincing nuclear chromogen, but the supplied HPA row does not identify a specific negative cell type (HPA: High in non-germinal center cells).
Positive control tissue: Appendix (Non-germinal center cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show BCL11B in MCF-7, RT-4, U2OS, with annotated localisation: Nucleoplasm (approved) (HPA subcellular).
Technical controls: Include no-primary (secondary-only) and matched nonimmune rabbit IgG controls, plus a BCL11B knockout specimen as a biological negative (selected-SKU caption: rabbit primary; standard IHC practice). Quench endogenous peroxidase for HRP/DAB detection and check the lymph node controls for pigment or nonspecific background (selected-SKU caption: HRP/DAB; standard IHC practice).
⚠️Feasibility: A target-specific fixation window and fixation effect are unreported, and the selected-SKU paraffin-section caption does not state the fixative (selected-SKU tissue-IHC caption: fixative not stated). The documented IHC example uses heat retrieval in EDTA at pH 8.0, so start there and assess retrieval alongside nuclear staining and background (selected-SKU tissue-IHC caption; UniProt Q9C0K0: nucleus). The supplied evidence does not establish whether frozen sections or IF are easier; lymph node HRP/DAB sections require attention to endogenous peroxidase and background (selected-SKU tissue-IHC caption: HRP/DAB; standard IHC practice).
HPA tissue IHC evidence for BCL11B
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Non-germinal center cells | High | Protein (IHC) | HPA → |
| Lymph node | Non-germinal center cells | High | Protein (IHC) | HPA → |
| Caudate | Neuronal cells | Medium | Protein (IHC) | HPA → |
| Cerebral cortex | Neuronal cells | Medium | Protein (IHC) | HPA → |
| Cervix | Squamous epithelial cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced BCL11B IHC Tips
Troubleshoot BCL11B staining in paraffin sections by checking retrieval, nuclear localisation, cell identity, and assay controls before interpreting chromogenic signal.
How should I retrieve BCL11B when nuclear staining is weak?
Start with heat-mediated antigen retrieval in EDTA at pH 8.0 for paraffin sections, matching the catalog antibody’s tissue IHC example (datasheet A01485-2). Include a positive control containing lymphoid or squamous epithelial cells, where nuclear staining is expected (HPA tissue IHC), and compare sections processed in the same run (standard IHC practice). The example used 2 μg/ml primary antibody overnight at 4°C; check that antibody incubation and detection worked before changing retrieval conditions (datasheet A01485-2; standard IHC practice). If staining remains weak, compare a second retrieval condition on adjacent sections while watching for tissue damage and increased background (standard IHC practice).
Could fixation explain weak BCL11B staining in my paraffin sections?
The catalog example identifies a paraffin-embedded section but does not state its fixative, so BCL11B-specific fixation sensitivity is unknown (datasheet A01485-2). Record the fixative, fixation duration, section age, and processing history for each specimen before comparing staining intensity across cases (standard IHC practice). Process a known positive control alongside the affected sections using EDTA retrieval at pH 8.0 and the same antibody incubation (datasheet A01485-2; standard IHC practice). If only one processing batch loses nuclear signal, investigate that batch and repeat staining on available sections before assigning a biological explanation (standard IHC practice; UniProt Q9C0K0 localisation).
What staining compartment should I accept as BCL11B positive?
Score a convincing nuclear signal: BCL11B is annotated as nuclear, and tissue IHC shows nuclear expression in selected cells (UniProt Q9C0K0 localisation; HPA tissue IHC). The nucleoplasm is the approved main location, with an additional nucleolar fibrillar-center location reported by subcellular imaging (HPA subcellular). Use a counterstain to confirm that chromogen overlies intact nuclei, then assess the relevant cell population instead of treating diffuse cytoplasmic colour as equivalent signal (standard IHC practice; HPA tissue IHC). If staining appears only at section edges or outside nuclei, review morphology, retrieval, and detection controls before calling the specimen positive (standard IHC practice).
Can epitope selection or isoforms change the BCL11B IHC result?
UniProt lists 2 BCL11B isoforms and multiple modified residues, including phosphorylated positions 97, 110, 120, 129, and 256 (UniProt Q9C0K0). The supplied tissue IHC caption does not identify the antibody epitope or establish isoform-specific recognition, so do not assign a staining difference to either isoform (datasheet A01485-2). For discordant cases, document the antibody’s stated immunogen or epitope if available, and compare an independent epitope only after its paraffin-section performance is established (standard IHC practice). Interpret any difference against nuclear localisation and cell identity, because staining intensity alone cannot identify a BCL11B modification or isoform (UniProt Q9C0K0; standard IHC practice).
How can I check a BCL11B finding with multiplex IF?
For a secondary IF experiment, pair BCL11B with a marker identifying the expected cell population, such as a T-cell marker in lymphoid tissue, and require nuclear BCL11B signal within those cells (UniProt Q9C0K0 function; HPA tissue IHC). Choose fluorophores after checking tissue autofluorescence and use single-channel controls to assess bleed-through before interpreting colocalisation (standard IF practice). BCL11B has no transmembrane segment and is nuclear, so permeabilisation must allow antibody access to the nucleus (UniProt Q9C0K0 topology and localisation; standard IF practice). The supplied catalog example establishes a chromogenic paraffin-section workflow, while its caption supplies no IF fixation or permeabilisation conditions to transfer (datasheet A01485-2).
How do I reduce diffuse brown staining without losing BCL11B-positive nuclei?
First distinguish crisp nuclear staining from diffuse colour in stroma, damaged tissue, or section edges using morphology and a matched negative control (UniProt Q9C0K0 localisation; standard IHC practice). The catalog example blocked with 10% goat serum and used 2 μg/ml primary antibody overnight at 4°C (datasheet A01485-2). Check the peroxidase block and a no-primary control when using HRP with DAB, because endogenous enzyme activity and detection reagents can produce chromogen independently of BCL11B (datasheet A01485-2; standard IHC practice). If background persists, adjust blocking, washing, antibody concentration, or chromogen development one variable at a time while retaining a positive nuclear control (standard IHC practice).
How should I quantify BCL11B across heterogeneous tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell compartment before scoring: HPA reports nuclear BCL11B in subsets of lymphoid cells, squamous epithelia, neurons, and testis (HPA tissue IHC). For a defined cell population, report the percentage of positive nuclei and, when intensity is reproducible, an H-score based on the fractions at each intensity (standard IHC practice). For spatial comparisons, report positive nuclei per mm² of viable tissue and also the number of eligible cells assessed (standard IHC practice). Normalise comparisons to the same cell type, sampled area, staining batch, and scoring threshold, excluding necrosis and edge artefacts before comparing cases (standard IHC practice).
How can I tell true BCL11B expression from an IHC artefact?
A credible positive result shows nuclear staining in an intact, identifiable cell population; BCL11B is nuclear and HPA reports expression in selected lymphoid and squamous epithelial cells (UniProt Q9C0K0 localisation; HPA tissue IHC). Check whether apparent positives are confined to cut edges, necrotic regions, or extracellular deposits, which should be excluded from interpretation (standard IHC practice). Use a no-primary control and an adequate peroxidase block to investigate brown signal arising from detection reagents or endogenous enzyme activity (standard IHC practice). Interpret unexpected positive cell types cautiously: HPA rates its tissue IHC evidence as Enhanced but reports only medium agreement with RNA data and pending external verification (HPA tissue IHC).
Boster reagents
Best BCL11B / B-cell lymphoma/leukemia 11B IHC Antibodies
Both antibodies list human reactivity and have tissue IHC images (catalog reactivity; IHC captions). The images also cover mouse and rat spleen IHC (M01485-2 IHC captions) and U2OS IF (A01485-2 IF caption).
Real IHC data
Anti-BCL11B Antibody ®
Cat # A01485-2
Real IHC data
Anti-Ctip2 Rabbit Monoclonal Antibody
Cat # M01485-2
A01485-2 lists human and rat reactivity, with human paraffin-section IHC images and U2OS IF/ICC imaging (catalog reactivity and applications; A01485-2 IHC/IF captions). M01485-2 lists human, mouse and rat reactivity and IHC images of human tonsil, mouse spleen and rat spleen; IF is listed as an application (catalog reactivity and applications; M01485-2 IHC captions).
Which to pick: Choose A01485-2 for human paraffin-section IHC with a documented retrieval and detection workflow, or for IF/ICC with a documented U2OS image (A01485-2 IHC/IF captions; catalog applications). Choose M01485-2 when mouse, rat or human tissue IHC is needed: it is monoclonal and has spleen and tonsil IHC images, with an IHC starting range of 1:200–1:1000 (catalog clonality and dilution; M01485-2 IHC captions). The A01485-2 IHC captions specify paraffin sections, but neither SKU’s IHC captions report the fixative (A01485-2 and M01485-2 IHC captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9C0K0 (BC11B_HUMAN, B-cell lymphoma/leukemia 11B).
- Human Protein Atlas. BCL11B tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. BCL11B subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the nucleoli fibrillar center..
- Human Protein Atlas. BCL11B antibody validation summary (1 antibodies).
- BCL11B expression in hepatocellular carcinoma relates to chemosensitivity and clinical prognosis. Cancer medicine 2023 — PMC10417273.
- High Specificity of BCL11B and GLG1 for EWSR1-FLI1 and EWSR1-ERG Positive Ewing Sarcoma. Cancers 2020 — PMC7139395.
- Reactivation of corticogenesis-related transcriptional factors BCL11B and SATB2 after ischemic lesion of the adult mouse brain. Scientific reports 2023 — PMC10220074.
- BCL11B regulates epithelial proliferation and asymmetric development of the mouse mandibular incisor. PloS one 2012 — PMC3358280.
- PubMed PMID:11719382 — UniProt-cited evidence.
- PubMed PMID:12565905 — UniProt-cited evidence.
- PubMed PMID:16809611 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for BCL11B (B-cell lymphoma/leukemia 11B). Expected localisation Nuclear staining in subsets of tissue cells (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A01485-2). Validated IHC antibody: A01485-2 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Non-germinal center cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human bladder urothelial carcinoma with squamous differentiation tissue; fixative not…; 2. Fixation: Image fixative and duration unreported (datasheet A01485-2); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A01485-2); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A01485-2); 8. Primary antibody: Rabbit anti-BCL11B, 2-5 μg/ml (datasheet A01485-2); 9. Primary incubation: Overnight at 4 °C (datasheet A01485-2). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A01485-2); Caveat: Subset staining; RNA concordance is medium (HPA tissue IHC); Isoform / epitope: Two isoforms ; verify epitope coverage (UniProt); Regulation: High in brain and malignant T-cell lines (UniProt). Evidence: UniProt Q9C0K0, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet A01485-2, PMC10417273, PMC7139395. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/BCL11B/immunohistochemistry-ihc-guide.